Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.
This is a division of application No. 09/480,889, filed Jan. 11, 2000 now U.S. Pat. No. 6,399,826, which is a continuation-in-part of U.S. Application Ser. No. 09/372,158, filed Aug.11, 1999 now U.S. Pat. No. 6,331,571, both of which are incorporated herein by reference.
Methods of making and using racemic and optically pure metabolites of sibutramine, and pharmaceutically acceptable salts, solvates, and clathrates thereof, are disclosed. Pharmaceutical compositions and dosage forms are also disclosed which comprise a dopamine reuptake inhibitor, such as a racemic or optically pure sibutramine metabolite, and optionally an additional pharmacologically active compound.
